Publications
- Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy
- Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation
- A mass cytometry method pairing T cell receptor and differentiation state analysis
- Breaking up the CD8<sup>+</sup> T cell: Treg pas de deux
- Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation
- A mass cytometry approach to track the evolution of T cell responses during infection and immunotherapy by paired T cell receptor repertoire and T cell differentiation state analysis
- Separating the Good from the Bad: Tumor-Infiltrating Tregs Have Increased Fucosylation
- CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8<sup>+</sup> T cell antitumor immunity
- BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes
- A PRC1-RNF2 knockout punch for cancer
- MHC-II neoantigens shape tumour immunity and response to immunotherapy.
- Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation.
- Treg programming and therapeutic reprogramming in cancer.
- Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
- Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.
- The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.
- Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability.
- Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.
